(NASDAQ: BCEL) Atreca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.66%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Atreca's revenue in 2023 is $0.On average, 1 Wall Street analysts forecast BCEL's revenue for 2024 to be $1,981,203,750, with the lowest BCEL revenue forecast at $1,981,203,750, and the highest BCEL revenue forecast at $1,981,203,750. On average, 1 Wall Street analysts forecast BCEL's revenue for 2025 to be $1,981,203,750, with the lowest BCEL revenue forecast at $1,981,203,750, and the highest BCEL revenue forecast at $1,981,203,750.
In 2027, BCEL is forecast to generate $1,981,203,750 in revenue, with the lowest revenue forecast at $1,981,203,750 and the highest revenue forecast at $1,981,203,750.